• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.

作者信息

Verma Subodh, McGuire Darren K, Kosiborod Mikhail N

机构信息

St Michael's Hospital and the University of Toronto, Canada (S.V.).

University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.).

出版信息

Circulation. 2020 Dec 8;142(23):2201-2204. doi: 10.1161/CIRCULATIONAHA.120.051122. Epub 2020 Sep 24.

DOI:10.1161/CIRCULATIONAHA.120.051122
PMID:32969716
Abstract
摘要

相似文献

1
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.两个故事：一个篇章：EMPEROR-Reduced研究与DAPA-HF研究
Circulation. 2020 Dec 8;142(23):2201-2204. doi: 10.1161/CIRCULATIONAHA.120.051122. Epub 2020 Sep 24.
2
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
3
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.DAPA-HF 试验：心力衰竭之战的重大胜利。
Cell Metab. 2019 Nov 5;30(5):847-849. doi: 10.1016/j.cmet.2019.10.008.
4
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).恩格列净治疗射血分数降低的心力衰竭患者的随机临床试验（Empire HF）。
Trials. 2019 Jun 21;20(1):374. doi: 10.1186/s13063-019-3474-5.
5
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).一项评估钠-葡萄糖协同转运蛋白 2 抑制剂达格列净对射血分数降低的心力衰竭患者发病率和死亡率影响的试验（DAPA-HF）。
Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21.
6
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.从 DAPA-HF 试验中吸取的有关 SGLT2 抑制剂在其他即将完成的大规模试验背景下对心力衰竭事件的获益机制的经验教训。
Cardiovasc Diabetol. 2019 Oct 4;18(1):129. doi: 10.1186/s12933-019-0938-6.
7
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.在 EMPEROR-Preserved 试验中射血分数保留型心力衰竭患者的基线特征。
Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064.
8
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.达格列净和恩格列净在真实心力衰竭人群中的应用资格。
J Card Fail. 2022 Jul;28(7):1050-1062. doi: 10.1016/j.cardfail.2022.04.011. Epub 2022 May 10.
9
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.恩格列净对射血分数降低的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Reduced 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.
10
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.恩格列净作为附加疗法对因急性失代偿性心力衰竭住院的糖尿病患者的充血和肾功能的影响：一项前瞻性随机对照研究。
Circ Heart Fail. 2021 Mar;14(3):e007048. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Epub 2021 Mar 5.

引用本文的文献

1
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.钠-葡萄糖协同转运蛋白2抑制剂：从降血糖到心血管获益
Cardiovasc Res. 2024 Apr 30;120(5):443-460. doi: 10.1093/cvr/cvae047.
2
Prognostic significance of serum dynamin‑related protein 1 in patients with heart failure: Findings from a prospective observational study.血清动力相关蛋白1在心力衰竭患者中的预后意义：一项前瞻性观察性研究的结果
Exp Ther Med. 2024 Jan 29;27(3):115. doi: 10.3892/etm.2024.12404. eCollection 2024 Mar.
3
Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
钠-葡萄糖共转运蛋白 2 抑制剂治疗射血分数保留的心力衰竭和伴有或不伴有 2 型糖尿病的慢性肾脏病：叙事性综述。
Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y.
4
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.左西孟旦治疗晚期心力衰竭的间歇性正性肌力支持：LEVO-D 注册研究。
ESC Heart Fail. 2023 Apr;10(2):1193-1204. doi: 10.1002/ehf2.14278. Epub 2023 Jan 19.
5
SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.2型糖尿病与心力衰竭中的钠-葡萄糖协同转运蛋白2抑制剂——简要综述
J Clin Med. 2022 Mar 8;11(6):1470. doi: 10.3390/jcm11061470.
6
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.钠-葡萄糖共转运蛋白 2 抑制剂与心脏重构。
J Cardiovasc Transl Res. 2022 Oct;15(5):944-956. doi: 10.1007/s12265-022-10220-5. Epub 2022 Mar 15.
7
Empagliflozin-A New Chance for Patients with Chronic Heart Failure.恩格列净——慢性心力衰竭患者的新希望。
Pharmaceuticals (Basel). 2021 Dec 30;15(1):47. doi: 10.3390/ph15010047.
8
Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds" Approach?糖尿病与心力衰竭的交集：SGLT2i 是否是“一石二鸟”的方法？
Curr Cardiol Rep. 2021 Oct 13;23(11):171. doi: 10.1007/s11886-021-01591-3.